RxDoctor Payments Data

Rachel Eidelman, MD

Cardiovascular Disease · Boynton Beach, FLNPI 1518941012

Payments from drug & device makers

$9,507in general payments, 2019–2025

Across 441 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Novartis$657
  • Boehringer Ingelheim$611
  • Boston Scientific$583
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$9,472100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,507 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$309,307
Medicare patients
1,302
Services billed
3,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$249,205
XareltoRivaroxaban145$175,967
EntrestoSacubitril/Valsartan112$135,767
Repatha SureclickEvolocumab130$105,150
FarxigaDapagliflozin Propanediol80$65,652
Repatha PushtronexEvolocumab28$28,021
MultaqDronedarone Hcl19$18,208
Praluent PenAlirocumab24$16,519
BrilintaTicagrelor24$15,570
VascepaIcosapent Ethyl19$12,065
NexlizetBempedoic Acid/Ezetimibe23$9,746
Metoprolol Succinate441$6,567
Ranolazine ErRanolazine47$4,913
Ezetimibe227$4,402
Atorvastatin Calcium552$4,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$249,205215 claims
Johnson & JohnsonXarelto$1,142$175,967145 claims
NovartisEntresto$657$135,767112 claims
AstraZenecaFarxiga, Brilinta$1,188$81,222104 claims
Sanofi-aventis U.S. LLCMultaq$319$18,20819 claims
Esperion Therapeutics, Inc.Nexlizet$557$9,74623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →